Skip to main content
Top
Published in: International Journal of Hematology 1/2009

01-07-2009 | Case Report

Polymyositis and myocarditis after donor lymphocyte infusion

Authors: Jae-Sook Ahn, Sang-Hee Cho, Yeo-Kyeoung Kim, Deok-Hwan Yang, Woo Kyun Bae, Hyun Jeong Shim, Je-Jung Lee, Ik-Joo Chung, Sang Woo Juhng, Hyeoung-Joon Kim

Published in: International Journal of Hematology | Issue 1/2009

Login to get access

Abstract

Chronic graft versus host disease (GVHD) is a common late complication of hematopoietic stem cell transplantation. Polymyositis is a rare manifestation of chronic GVHD after donor lymphocyte infusion (DLI). Patients with both polymyositis and myocarditis have not been reported to date. Here, we report an 18-year-old female patient who developed polymyositis and myocarditis after a DLI. The patient developed the symptoms of fever, generalized myalgia, dysarthria, and asymptomatic sinus tachycardia at DLI day +102, and 17 days after the discontinuation of immunosuppressants. The laboratory testing showed elevated muscle enzymes, and the electromyographic examination revealed myopathic abnormalities compatible with the diagnosis of myositis. The muscle biopsy showed CD8+ T cell infiltration of the muscle fibers. The electrocardiogram (ECG) showed sinus tachycardia with an incomplete right bundle branch block, anteroseptal ST elevation and lateral ST depression. Echocardiography showed mild hypokinesia of the left interventricular septal wall without evidence of infection or leukemic relapse. The patient was immediately treated with 60 mg/day of prednisone and tacrolimus after the diagnosis of polymyositis and myocarditis, apparently associated with chronic GVHD. The cardiac and muscle enzymes decreased and the ECG normalized after immunosuppressant treatment. The follow-up ECG 2 weeks after initiation of therapy was normal.
Literature
8.
go back to reference Silberstein L, Davies A, Kelsey S, et al. Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation and subsequent donor lymphocyte infusion. Bone Marrow Transplant. 2001;27:231–3. doi:10.1038/sj.bmt.1702775.CrossRefPubMed Silberstein L, Davies A, Kelsey S, et al. Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation and subsequent donor lymphocyte infusion. Bone Marrow Transplant. 2001;27:231–3. doi:10.​1038/​sj.​bmt.​1702775.CrossRefPubMed
9.
go back to reference Platzbecker U, Klingel K, Thiede C, et al. Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin. Bone Marrow Transplant. 2001;27:107–9. doi:10.1038/sj.bmt.1702744.CrossRefPubMed Platzbecker U, Klingel K, Thiede C, et al. Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin. Bone Marrow Transplant. 2001;27:107–9. doi:10.​1038/​sj.​bmt.​1702744.CrossRefPubMed
11.
go back to reference Jadus MR, Wepsic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant. 1992;10:1–14.PubMed Jadus MR, Wepsic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant. 1992;10:1–14.PubMed
Metadata
Title
Polymyositis and myocarditis after donor lymphocyte infusion
Authors
Jae-Sook Ahn
Sang-Hee Cho
Yeo-Kyeoung Kim
Deok-Hwan Yang
Woo Kyun Bae
Hyun Jeong Shim
Je-Jung Lee
Ik-Joo Chung
Sang Woo Juhng
Hyeoung-Joon Kim
Publication date
01-07-2009
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0332-3

Other articles of this Issue 1/2009

International Journal of Hematology 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine